Home » Enzon Opens a Phase II Study of PEG-SN38 for Metastatic Breast Cancer
Enzon Opens a Phase II Study of PEG-SN38 for Metastatic Breast Cancer
Enzon Pharmaceuticals, Inc. Wednesday announced that the first
patient has been treated in the Phase 2 studies of PEG-SN38 for metastatic breast cancer.
Earth Times
Earth Times
Upcoming Events
-
07May
-
14May
-
30May